An intensive and in-depth two day conference providing an advanced level update
Conference Date: 4 & 5 February 2015
Venue: The Rembrandt Hotel, London
Conference Ref: A2 - 6015
Novel Approaches to the Treatment of Cancer
Introduction and Conference Objectives
In the last two decades, there has been a paradigm shift in the way that anticancer drugs are developed, from surgery, irradiation and cytotoxic agents to targeted antibody therapeutics and small molecules, and, precision radiotherapy. The shift to targeted therapies has affected oncology drug development strategies, allowing greater specificity, improved efficacy and lower toxicity.
This advanced level conference will provide an invaluable update on novel approaches for those in the main stream drug industry and biotech companies involved in clinical development research into new anti-cancer agents. It will be of particular importance to those responsible for Phase 1, II and III development programmes.
The conference has selected key topics of interest to those involved in clinical development research, including new paradigms for targeted therapies, novel approaches to the treatment of breast cancer and melanoma, novel approaches to the treatment of pancreatic cancer, drug development and precision radiotherapy, European drug development initiatives, gene and cell therapies and cancer vaccines. As well, the conference will provide an update on the regulatory aspects of cancer drugs including regulatory issues in marketing authorisations and early market access.
Conference to be chaired by:
Professor Karol Sikora, Chief Medical Officer, Cancer Partners UK
Professor David Thurston, Professor of Drug Discovery, King's College, London
Distinguished speakers include:
Dr Tobi Arkenau, Director of Drug Development, Sarah Cannon Research UK
Professor Angus Dalgleish, Professor of Oncology, St George's University of London
Dr Beatriz Flores De Laurnaga, Senior Medical Adviser, MHRA
Dr Mark Harries, Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust
Professor Robert Hawkins, Honorary Consultant in Medical Oncology, University of Manchester and The Christie
Rod Murphy, Chairman, ABPI Cancer Working Group
Professor Stephen Neidle, Research Director, UCL School of Pharmacy
Professor Heinz Zwierzina, Chairman of the BDA, Professor of Internal Medicines, Innsbruck Medical University
Who should attend?
This important conference will be of interest to clinicians, scientists and academics involved in clinical development research into new anti-cancer agents from the pharmaceutical and biotech industries, as well as those involved in clinical development research in hospitals and universities. People who should register now include: medical directors and associate medical directors as well as senior medical advisers; directors of regulatory affairs and drug safety, strategic and clinical trial planners and project managers in product development, drug safety, regulatory affairs and marketing.
Karol Sikora is Chief Medical Officer of CancerPartnersUK which is creating the largest independent UK cancer network working with both NHS and private patients. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He is Dean and Professor of Medicine at Britain's first independent Medical School at the University of Buckingham and Fellow of Corpus Christi College, Cambridge.
Professor David E. Thurston
David Thurston is Professor of Drug Discovery in the Institute of Pharmaceutical Science (IPS) and the Department of Pharmacy at King's College London. David's research team discovered the first-in-class DNA sequence-selective agent SJG-136 (a PBD Dimer), which has reached Phase II clinical trials in ovarian cancer and leukaemia. In 2000 he co-founded the oncology biotech company Spirogen Ltd for which he was Chief Scientific Officer until 2012. The company was acquired by AstraZeneca in 2013 to use PBD Dimers as payloads for Antibody-Drug Conjugates (ADCs). One ADC (SGN-CD33A), based on a PBD Dimer and targeted to the CD33 antigen expressed on the surface of myeloblasts in AML patients, is presently in Phase I clinical trials with Seattle Genetics, and other PBD-based ADCs are in late-stage pre-clinical development.
David has authored many papers in the areas of medicinal chemistry and drug discovery, and is author of the text book "Chemistry and Pharmacology of Anticancer Drugs". He is also Editor-in-Chief for the Royal Society of Chemistry's "RSC Drug Discovery" series of books. He has been a member of the Committee on Safety of Medicines (CSM), and has chaired the Chemistry, Pharmacy & Standards (CPS) Sub-Committee of the CSM. David is a Fellow of the Royal Pharmaceutical Society and the Academy of Pharmaceutical Sciences.
MD FRACP FRCP FRCPath FMedSci
Professor of Oncology
Angus Dalgleish trained at University College Hospital, where he also did an intercalated degree in anatomy with Professor J Z Young. Following house jobs he took a position with the Flying Doctor Service in Australia for one year and stayed on to train in internal medicine and oncology at hospitals in Brisbane and Sydney. He returned to the U.K. in 1984 and undertook a thesis on retroviruses with Robert Weiss. He was then appointed as Senior Clinical Scientist at the MRC Clinical Research Centre at Northwick Park where he pursued his interests in HIV pathogenesis and the potential of Thalidomide to treat chronic disease. His suggestion that analogues of Thalidomide could lead to enhancement of the therapeutic activity and reduction of the side effects was taken up by David Stirling of Celgene and this partnership led to the licensing of Revlimid (Lenalidomide) and Pomalidomide (Pomalyst) for myeloma and lymphoma. He was awarded the Joshua Lederberg prize in 2011 in recognition of this work.
Since 1991 he has been Professor of Oncology at St. George's University of London. During this time he has focussed on the immunotherapy of cancer and has conducted numerous clinical trials involving a variety of vaccines and immunotherapy. Since 2001 he has been the Principal of the Cancer Vaccine Institute, currently focussing on the revival of the Mycobacterium based vaccines that were dropped by SR Pharma and now resurrected by Immodulon. He is on numerous scientific advisory boards involving the development of vaccines and immunotherapy, including Celgene, Immodulon, Curevac, Bionor Pharma and TNI Biotech. He was Chief Investigator of a randomised clinical trial in patients with metastatic pancreatic cancer for Immodulon (IMM-101) and Gemcitabine versus Gemcitabine alone, which has shown a significant survival advantage for the IMM-101 combination with no significant toxicities. It will be presented in early 2015. In addition, his observations that Revlimid is co-stimulatory when given with vaccines has been confirmed in a randomised study of a therapeutic vaccine for HIV, where it significantly increased the CD4 counts which have not responded to HAART or the vaccine alone.
Professor Stephen Neidle is a graduate of Imperial College. He was appointed to the Chair of Biophysics at the Institute of Cancer Research in 1990 (where he was also Academic Dean 1997-2002) and moved to the new Chair of Chemical Biology at the School of Pharmacy, University College London in 2002. He is a Professorial Fellow of Cancer Research UK.
Stephen Neidle's research interests are primarily in the chemistry and biology of nucleic acid structure and recognition by small molecules, and in exploiting this information for the rational design of new anti-cancer and anti-infective agents. He has pioneered studies on the structure and recognition of G-quadruplex nucleic acids as novel therapeutic targets, using an integrated multi-disciplinary structural, chemical and biological approach and has published over 475 papers and reviews, 10 patents, and has written and edited a number of books on nucleic acids, drug-DNA interactions and cancer drug discovery. His current h index is 76.
Stephen Neidle has been involved in the discovery of several experimental and clinically-approved drugs. Most recently a new antibiotic, SMT19969 has recently entered Phase II clinical trials. This compound is selective for the treatment of C. difficile infections, and is closely related to earlier compounds invented by Stephen Neidle and Professor John Mann, then at Queen's University Belfast, The trials are being undertaken by Summit plc, an Oxford, UK based drug discovery company.
Professor Heinz Zwierzina
Professor Heinz Zwierzina is the Chairman of the CDDF.
He is currently Professor of Internal Medicine at Innsbruck University in Austria. His specialisation is in hematology and oncology.
He is an active member in many scientific research organisations and is sitting on numerous committees of international research bodies including the EORTC, National Cancer Institute (NCI), Cancer Research UK and European School of Oncology (ESO).
He has co-ordinated a grant of the European commission (BIOMED) "Organisation of preclinical and clinical research of anticancer therapy with biological response modifiers" and is a member of the European Commission-funded Euregenethy project "Harmonisation of gene therapy throughout Europe".
He was the founder and previous chairman of the EORTC Biological Therapeutics Development Group which is composed of pre-clinical and clinical scientists.
In addition, he has published over 80 papers in peer-reviewed scientific journals and books, chaired/presented at numerous international meetings and is a member of the editorial board or reviewer for more than 15 international scientific journals.
He has extensive experience in early drug development with biological agents as well as the combination of biological agents with chemotherapy, e.g. angiogenesis inhibitors therapeutic antibodies vaccines signal transduction inhibitors immunomodulators gene therapy. One of his major interests in drug development is the definition and use of surrogate markers (e.g. proteomics, functional imaging etc.) in phase I/II cancer clinical trials in order to speed up and reduce the costs of the overall drug development programs.